Literature DB >> 12032335

Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets.

Bianca Rocca1, Paola Secchiero, Giovanni Ciabattoni, Franco O Ranelletti, Lucia Catani, Lia Guidotti, Elisabetta Melloni, Nicola Maggiano, Giorgio Zauli, Carlo Patrono.   

Abstract

Cyclooxygenase (COX)-1 or -2 and prostaglandin (PG) synthases catalyze the formation of various PGs and thromboxane (TX) A(2). We have investigated the expression and activity of COX-1 and -2 during human megakaryocytopoiesis. We analyzed megakaryocytes from bone marrow biopsies and derived from thrombopoietin-treated CD34(+) hemopoietic progenitor cells in culture. Platelets were obtained from healthy donors and patients with high platelet regeneration because of immune thrombocytopenia or peripheral blood stem cell transplantation. By immunocytochemistry, COX-1 was observed in CD34(+) cells and in megakaryocytes at each stage of maturation, whereas COX-2 was induced after 6 days of culture, and remained detectable in mature megakaryocytes. CD34(+) cells synthesized more PGE(2) than TXB(2) (214 +/- 50 vs. 30 +/- 10 pg/10(6) cells), whereas the reverse was true in mature megakaryocytes (TXB(2) 8,440 +/- 2,500 vs. PGE(2) 906 +/- 161 pg/10(6) cells). By immunostaining, COX-2 was observed in <10% of circulating platelets from healthy controls, whereas up to 60% of COX-2-positive platelets were found in patients. A selective COX-2 inhibitor reduced platelet production of both PGE(2) and TXB(2) to a significantly greater extent in patients than in healthy subjects. Finally, we found that COX-2 and the inducible PGE-synthase were coexpressed in mature megakaryocytes and in platelets. We conclude that both COX-isoforms contribute to prostanoid formation during human megakaryocytopoiesis and that COX-2-derived PGE(2) and TXA(2) may play an unrecognized role in inflammatory and hemostatic responses in clinical syndromes associated with high platelet turnover.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032335      PMCID: PMC124306          DOI: 10.1073/pnas.112202999

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance.

Authors:  A A Weber; K C Zimmermann; J Meyer-Kirchrath; K Schrör
Journal:  Lancet       Date:  1999-03-13       Impact factor: 79.321

2.  COX-2 is not involved in thromboxane biosynthesis by activated human platelets.

Authors:  P Patrignani; M G Sciulli; S Manarini; G Santini; C Cerletti; V Evangelista
Journal:  J Physiol Pharmacol       Date:  1999-12       Impact factor: 3.011

3.  p45 NF-E2 regulates expression of thromboxane synthase in megakaryocytes.

Authors:  S Deveaux; S Cohen-Kaminsky; R A Shivdasani; N C Andrews; A Filipe; I Kuzniak; S H Orkin; P H Roméo; V Mignotte
Journal:  EMBO J       Date:  1997-09-15       Impact factor: 11.598

4.  In vitro senescence and apoptotic cell death of human megakaryocytes.

Authors:  G Zauli; M Vitale; E Falcieri; D Gibellini; A Bassini; C Celeghini; M Columbaro; S Capitani
Journal:  Blood       Date:  1997-09-15       Impact factor: 22.113

Review 5.  Platelet kinetics.

Authors:  G L Dale
Journal:  Curr Opin Hematol       Date:  1997-09       Impact factor: 3.284

6.  Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development.

Authors:  B Rocca; L M Spain; E Puré; R Langenbach; C Patrono; G A FitzGerald
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

7.  Prostaglandin D synthase in human megakaryoblastic cells.

Authors:  I Mahmud; N Ueda; H Yamaguchi; R Yamashita; S Yamamoto; Y Kanaoka; Y Urade; O Hayaishi
Journal:  J Biol Chem       Date:  1997-11-07       Impact factor: 5.157

8.  Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target.

Authors:  P J Jakobsson; S Thorén; R Morgenstern; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

9.  Effect of thrombopoietin on the development of megakaryocytes and platelets: an ultrastructural analysis.

Authors:  D Zucker-Franklin; K Kaushansky
Journal:  Blood       Date:  1996-09-01       Impact factor: 22.113

10.  Differential expression of thromboxane A synthase and prostaglandin H synthase in megakaryocytic cell line.

Authors:  N Matijevic-Aleksic; S K Sanduja; L H Wang; K K Wu
Journal:  Biochim Biophys Acta       Date:  1995-11-09
View more
  53 in total

Review 1.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John W Eikelboom; Jack Hirsh; Frederick A Spencer; Trevor P Baglin; Jeffrey I Weitz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes.

Authors:  Faouzi Addad; Tahar Chakroun; Ismail Elalamy; Fatma Abderazek; Saoussen Chouchene; Zohra Dridi; Gregoris T Gerotziafas; Mohamed Hatmi; Mohsen Hassine; Habib Gamra
Journal:  Int J Hematol       Date:  2010-08-20       Impact factor: 2.490

3.  Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling.

Authors:  Dan A Dixon; Neal D Tolley; Kristi Bemis-Standoli; Mark L Martinez; Andrew S Weyrich; Jason D Morrow; Stephen M Prescott; Guy A Zimmerman
Journal:  J Clin Invest       Date:  2006-09-21       Impact factor: 14.808

Review 4.  Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function.

Authors:  Guy A Zimmerman; Andrew S Weyrich
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-03       Impact factor: 8.311

Review 5.  Pharmacology of antiplatelet agents.

Authors:  Kiran Kalra; Christopher J Franzese; Martin G Gesheff; Eli I Lev; Shachi Pandya; Kevin P Bliden; Udaya S Tantry; Paul A Gurbel
Journal:  Curr Atheroscler Rep       Date:  2013-12       Impact factor: 5.113

Review 6.  Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum.

Authors:  Adriana Vieira-de-Abreu; Robert A Campbell; Andrew S Weyrich; Guy A Zimmerman
Journal:  Semin Immunopathol       Date:  2011-08-06       Impact factor: 9.623

Review 7.  Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents.

Authors:  Marco Zimarino; Giulia Renda; Raffaele De Caterina
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene.

Authors:  Patricia McGettigan; Lisa F Lincz; John Attia; Patrick McElduff; Linda Bissett; Roseanne Peel; Barrie Stokes; Stephen Hancock; Kim Henderson; Michael Seldon; David Henry
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 9.  Amicus or Adversary Revisited: Platelets in Acute Lung Injury and Acute Respiratory Distress Syndrome.

Authors:  Elizabeth A Middleton; Matthew T Rondina; Hansjorg Schwertz; Guy A Zimmerman
Journal:  Am J Respir Cell Mol Biol       Date:  2018-07       Impact factor: 6.914

Review 10.  Monitoring aspirin and clopidogrel response: testing controversies and recommendations.

Authors:  Athanasios Karathanos; Tobias Geisler
Journal:  Mol Diagn Ther       Date:  2013-06       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.